Close

Lexicon Pharma (LXRX) Granted European Commission Approval for XERMELO (Telotristat Ethyl)

September 19, 2017 12:36 PM EDT Send to a Friend
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) announced today that the European Commission has approved XERMELO® (telotristat ethyl) 250 mg as a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login